ADAR1 Capital Management LLC Increases Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

ADAR1 Capital Management LLC raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 16.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,508,694 shares of the company’s stock after acquiring an additional 483,244 shares during the period. Roivant Sciences makes up 8.3% of ADAR1 Capital Management LLC’s holdings, making the stock its 2nd largest position. ADAR1 Capital Management LLC owned 0.48% of Roivant Sciences worth $41,508,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. FMR LLC grew its stake in shares of Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after purchasing an additional 156,527 shares during the period. Vanguard Group Inc. grew its position in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock worth $521,553,000 after buying an additional 2,404,232 shares during the period. State Street Corp increased its stake in shares of Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after acquiring an additional 1,118,561 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Roivant Sciences by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company’s stock valued at $91,968,000 after acquiring an additional 26,727 shares during the period. Finally, Norges Bank bought a new position in Roivant Sciences during the 4th quarter worth approximately $52,443,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $9.46 on Monday. The company has a market capitalization of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.25. Roivant Sciences Ltd. has a 52 week low of $9.42 and a 52 week high of $13.06. The company’s 50 day moving average price is $10.62 and its two-hundred day moving average price is $11.32.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th.

Insider Activity

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the sale, the chief operating officer now directly owns 732,294 shares in the company, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock worth $15,028,538 over the last three months. Corporate insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.